We are dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases. We are advancing Calpain Inhibitor R&D work of Dr. Doron Greenbaum. Phelix Therapeutics solely-owns its innovative IP with a provisional patent, and has been awarded approximateky $5M in NIH funding for the development of cysteine protease inhibitors with an additional $200k for ongoing fibrosis work.